Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Rezolute, Inc. following significant stock losses due to disappointing clinical trial results for its lead drug candidate, ersodetug [2][4]. Group 1: Company Overview - Rezolute, Inc. is a publicly traded company listed on NASDAQ under the ticker RZLT [2]. - The company focuses on developing treatments for congenital hyperinsulinism, with ersodetug being its lead drug candidate [4]. Group 2: Clinical Trial Results - On December 11, 2025, Rezolute's shares experienced a sharp decline as the results from the Phase 3 sunRIZE clinical trial were released [4]. - The trial failed to meet both primary and key secondary endpoints, with the highest dose showing reductions in hypoglycemia events that were not statistically significant compared to placebo [4]. Group 3: Legal Implications - Investors who suffered significant losses in Rezolute stock or options are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Rezolute, Inc. following a significant drop in its stock price due to disappointing clinical trial results for its lead drug candidate, ersodetug [4][5]. Group 1: Company Overview - Rezolute, Inc. is a publicly traded company listed on NASDAQ under the ticker RZLT [4]. - The company focuses on developing treatments for congenital hyperinsulinism, with ersodetug being its lead drug candidate [5]. Group 2: Recent Developments - On December 11, 2025, Rezolute's shares experienced a dramatic decline, falling from approximately $10.94 to an intraday low of around $0.90, marking an approximate 85-90% drop [6]. - The decline was triggered by the failure of the Phase 3 sunRIZE clinical trial for ersodetug, which did not meet its primary and key secondary endpoints, with the highest dose showing statistically insignificant reductions in hypoglycemia events compared to placebo [5]. Group 3: Legal Implications - Faruqi & Faruqi, LLP is encouraging investors who suffered significant losses in Rezolute stock or options to discuss their legal rights [1]. - The firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [4].

Financial Performance - The company reported a net loss of $40.924 million for the six months ended December 31, 2025, compared to a net loss of $31.108 million for the same period in 2024, indicating a 31% increase in losses year-over-year [14]. - The company reported a comprehensive loss of $40.870 million for the six months ended December 31, 2025, compared to a comprehensive loss of $30.965 million for the same period in 2024, reflecting a 32% increase [14]. - The Company incurred a net loss of $40.9 million and net cash used in operating activities amounted to $37.8 million for the six months ended December 31, 2025 [39]. - The Company reported a consolidated net loss of $22.77 million for the three months ended December 31, 2025, compared to a net loss of $15.73 million for the same period in 2024, representing a 44.5% increase in net loss year-over-year [130]. Assets and Liabilities - As of December 31, 2025, total assets decreased to $138.629 million from $175.490 million as of June 30, 2025, representing a decline of approximately 21% [12]. - The total liabilities decreased to $10.631 million as of December 31, 2025, from $13.363 million as of June 30, 2025, a reduction of approximately 20% [12]. - As of December 31, 2025, the Company had an accumulated deficit of $444.8 million, with cash and cash equivalents of $11.9 million and short-term investments in marketable debt securities of $121.0 million [39]. - The Company has total liabilities of $10.6 million, including current liabilities of $9.5 million, and is subject to a $25.0 million milestone payment upon regulatory approval of ersodetug [42]. Cash and Investments - Cash and cash equivalents at the end of the period were $11.944 million, down from $94.107 million at the beginning of the period, reflecting a decrease of approximately 87% [20]. - As of December 31, 2025, investments in marketable debt securities had an aggregate fair value of $121.0 million, scheduled to mature during the 12-month period ending December 31, 2026 [45]. - The Company did not recognize any allowance for credit losses or impairment related to investments in marketable debt securities for the six months ended December 31, 2025 [48]. - As of December 31, 2025, the total fair value of the Company's financial assets measured at fair value was $129.12 million, with $8.13 million classified as Level 1 and $120.99 million as Level 2 [117]. Research and Development - Research and development expenses increased to $27.497 million for the six months ended December 31, 2025, compared to $25.381 million in the same period of 2024, marking an 8% increase [14]. - Research and development expenses for the three months ended December 31, 2025, totaled $14.35 million, an increase from $12.63 million in the same period of 2024, reflecting a 13.6% year-over-year growth [130]. - The increase in R&D expenses was primarily due to a $1.6 million rise in R&D compensation and benefits, including $0.9 million in one-time severance benefits [175]. - R&D costs for ersodetug decreased by $3.2 million, primarily due to a $6.0 million reduction in drug substance and product manufacturing, partially offset by a $1.5 million increase in clinical trial costs for the congenital HI phase 3 study [184]. Workforce and Severance - The Company accrued approximately $1.5 million of one-time severance benefits due to a workforce reduction, which was paid in full in January 2026 [43]. - A reduction in workforce of 29 employees was announced on December 15, 2025, resulting in approximately $1.5 million of one-time severance expenses [132]. - The average number of R&D employees increased from 46 to 51 for the three months ended December 31, 2025, contributing to higher compensation costs [175]. Stock and Equity - The company issued 8,223,879 shares through cashless exercises of pre-funded warrants, contributing to an increase in common stock outstanding from 86,995,985 to 95,547,998 shares [17]. - The total shareholders' equity was $127.998 million, a decrease from $147.168 million as of September 30, 2025, reflecting a net loss of $22.774 million for the quarter [62]. - The Company granted stock options for 275,000 shares at an exercise price of $6.55 per share as inducement awards in August 2025, with a fair value of $1.3 million [77]. - The total share-based compensation expense for the six months ended December 31, 2025, was $5.942 million, compared to $2.845 million for the same period in 2024 [98]. Clinical Trials and Regulatory Matters - The company is currently enrolling in a Phase 3 clinical trial for a tumor HI indication ("upLIFT") and plans to meet with the FDA to discuss results from a previous Phase 3 trial that did not meet its endpoints [24]. - The sunRIZE Phase 3 clinical trial did not meet its primary or key secondary endpoints, with the study demonstrating reductions in hypoglycemia events but not statistically significant compared to the placebo group [136]. - The Company aims to achieve alignment with the FDA on the path forward in congenital hyperinsulinism and complete enrollment in the registrational tumor HI study in 2026 [135]. - The Phase 3 upLIFT study results are anticipated in the second half of 2026, following modifications agreed upon with the FDA [145]. Market and Product Development - The initial addressable pediatric market for congenital hyperinsulinism (HI) in the U.S. is estimated to be over 1,500 individuals, with potential growth as ersodetug is used in patients who are partially responsive to current treatments [143]. - The total addressable market for tumor HI is estimated to be approximately 3,000 patients in the U.S. annually, with 60% managed at National Cancer Institutes [158]. - Ersodetug has shown substantial reductions in GIR, leading to improved management of hypoglycemia in patients, with treatment durations ranging from several months to nearly 2 years [149]. - The company maintains an EAP for various HI indications, providing ersodetug on a compassionate use basis when other options have failed [148].

Financial Performance - As of December 31, 2025, cash, cash equivalents, and investments in marketable securities totaled $132.9 million, down from $167.9 million as of June 30, 2025[5]. - The net loss for Q2 fiscal 2026 was $22.8 million, compared to a net loss of $15.7 million for the same period in the previous year[7]. - The accumulated deficit as of December 31, 2025, was $444.8 million, compared to $403.9 million as of June 30, 2025[13]. Expenses - Research and development (R&D) expenses for Q2 fiscal 2026 were $14.3 million, an increase from $12.6 million in the same period last year, primarily due to higher clinical trial activities and employee-related expenses[6]. - General and administrative (G&A) expenses rose to $9.9 million in Q2 fiscal 2026, compared to $4.5 million in the prior year, driven by increased professional fees and severance benefits[7]. - The total operating expenses for Q2 fiscal 2026 were $24.2 million, up from $17.1 million in Q2 fiscal 2025[13]. Clinical Trials and Studies - In the sunRIZE Phase 3 study, reductions in hypoglycemia events were observed, but were not statistically significant compared to placebo[4]. - 75% of patients in the Expanded Access Program (EAP) achieved complete discontinuation of IV dextrose/total parenteral nutrition (TPN), supporting the efficacy of ersodetug[4]. - The company plans to meet with the FDA under Breakthrough Therapy Designation to discuss next steps for the ersodetug program[4]. - Enrollment for the upLIFT Phase 3 study is ongoing, with topline results expected in the second half of 2026[4].

Core Insights - Rezolute, Inc. reported financial results and business updates for the three months ended December 31, 2025, focusing on its late-stage rare disease treatment for hypoglycemia caused by hyperinsulinism [1] Financial Performance - Cash, cash equivalents, and investments in marketable securities were $132.9 million as of December 31, 2025, down from $167.9 million as of June 30, 2025 [7] - Research and development (R&D) expenses increased to $14.3 million for the second quarter of fiscal 2026, compared to $12.6 million for the same period a year ago, primarily due to increased clinical trial activities and higher employee-related expenses [8] - General and administrative (G&A) expenses rose to $9.9 million for the second quarter of fiscal 2026, up from $4.5 million for the same period a year ago, attributed to increased professional fees and employee-related expenses [9] - The net loss for the second quarter of fiscal 2026 was $22.8 million, compared to a net loss of $15.7 million for the same period a year ago [9] Clinical Development - The Phase 3 sunRIZE study of ersodetug for congenital hyperinsulinism did not meet its primary or key secondary endpoints, although reductions in hypoglycemia events were observed [6] - The ongoing upLIFT study for tumor hyperinsulinism is currently enrolling participants, with topline results expected in the second half of 2026 [6] - In January 2026, data from the Expanded Access Program indicated that 75% of tumor HI patients achieved complete discontinuation of IV dextrose/TPN, supporting the efficacy of ersodetug [6] Corporate Updates - Rezolute plans to meet with the FDA under Breakthrough Therapy Designation to discuss next steps for the ersodetug program following the sunRIZE study results [6] - A virtual Investor Event in November 2025 highlighted the commercial opportunities for ersodetug, featuring insights from leading physician experts on the unmet clinical need in hyperinsulinism [6]

Company Overview - Rezolute, Inc. is a company listed on NASDAQ under the ticker symbol RZLT [2] - The company is currently facing legal scrutiny due to significant stock losses experienced by investors [2][3] Recent Developments - On December 11, 2025, Rezolute's shares experienced a dramatic decline, dropping approximately 85-90% from a previous close of around $10.94 to an intraday low of approximately $0.90 [4][5] - This sharp decline was triggered by disappointing topline results from its Phase 3 sunRIZE clinical trial for ersodetug, which failed to meet both primary and key secondary endpoints [4] Clinical Trial Results - The Phase 3 clinical trial for ersodetug aimed at treating congenital hyperinsulinism did not show statistically significant reductions in hypoglycemia events compared to placebo [4]

Core Insights - Rezolute, Inc. is under investigation by Faruqi & Faruqi, LLP due to significant stock losses following disappointing results from its Phase 3 clinical trial for its lead drug candidate, ersodetug [2][3]. Group 1: Company Performance - Rezolute's shares experienced a dramatic decline on December 11, 2025, dropping from approximately $10.94 to an intraday low of around $0.90, marking an approximate 85-90% decrease [3][4]. - The Phase 3 sunRIZE clinical trial for ersodetug did not meet its primary and key secondary endpoints, with the highest dose showing non-significant reductions in hypoglycemia events compared to placebo [3]. Group 2: Legal and Investor Actions - Faruqi & Faruqi, LLP is encouraging investors who suffered significant losses in Rezolute stock or options to contact them to discuss potential legal options [1]. - The law firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [2].

Company Overview - Rezolute, Inc. is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI) [3] - The company's antibody therapy, ersodetug, is designed to treat all forms of HI and has been studied in clinical trials and real-world cases for both congenital and tumor HI [3] Upcoming Events - Management will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026, taking place on February 11-12, 2026, in New York [1] - One-on-one investor meetings will be held throughout the conference, and interested investors can contact their Guggenheim representative to schedule a meeting with the management team [2]

Group 1 - Rezolute, Inc. shares experienced a significant decline on December 11, 2025, due to disappointing topline results from its Phase 3 sunRIZE clinical trial for the drug candidate ersodetug, which is intended for treating congenital hyperinsulinism [5] - The clinical trial failed to meet both its primary and key secondary endpoints, with the highest dose showing reductions in hypoglycemia events that were not statistically significant compared to placebo [5] - Faruqi & Faruqi, LLP is investigating potential claims against Rezolute, Inc. for investors who suffered significant losses [2][4]

Core Viewpoint - Rezolute, Inc. is under investigation for potential violations of federal securities laws following disappointing results from its Phase 3 sunRIZE study evaluating ersodetug for congenital hyperinsulinism [1][2]. Group 1: Study Results - The Phase 3 sunRIZE study did not meet its primary endpoint, as results were "not statistically significant" compared to the placebo group, which showed a 40% improvement [2]. - The study also failed to meet its key secondary endpoint, which was similarly "not statistically significant" compared to the placebo [2]. - Management expressed disappointment and stated they are conducting a thorough evaluation to understand the study outcomes better [2]. Group 2: Stock Market Reaction - Following the announcement of the study results, Rezolute's stock price plummeted over 89%, opening at $1.21 per share [2].